UNSPSC 51373409: Ammonium/antimony/codeine/phenylephrine/potassium/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373409 Ammonium/antimony/codeine/phenylephrine/potassium/pyrilamine is a Commodity code that in practice captures pharmaceutical products and medical supplies state and local governments procure for correctional health care, community health programs, and emergency response. Recent solicitations show state corrections departments and county health authorities buying parenteral nutrition solutions, intravenous products, naloxone, and drug deactivation systems. The Washington State Department of Corrections, as the dominant recent buyer under this code, sources these items for delivery to multiple correctional facilities with stringent rapid-delivery requirements (24 hours for customized PN bags, 8 hours for other parenteral products). Issuing bodies include state department corrections divisions and county health departments; the code does not yet show significant school district, transit authority, or municipal involvement in recent opportunities.

The code shows recent activity concentrated in the Pacific Northwest and Southeast, with Washington State and Florida posting identifiable opportunities. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026 for parenteral products, services, and equipment across eight facilities, with responses due October 7, 2026, and a pre-bid conference scheduled for September 23, 2026; the DOC encourages participation from small, minority-owned, women-owned, and veteran-owned businesses under state set-aside goals and anticipates selecting up to three contractors per region through June 30, 2030. Seminole County, Florida, issued IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries; that bid closed July 26, 2023 (a date inconsistency in the source). Both opportunities require demonstrated delivery performance, appropriate licensure, NCIC or background clearance, and specified insurance coverages including professional liability and cyber liability where applicable.